This study will investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of
single oral administration of 5 mg, 15 mg, 20 mg and 25 mg of SSS17 compared with placebo,
and evaluate the efficacy, safety, tolerance, pharmacokinetics and pharmacodynamics of
multiple oral administration of 15 mg and 20 mg of SSS17 compared with placebo. In addition,
the study will assess the effect of food on the pharmacokinetics of SSS17.
Phase:
Phase 1
Details
Lead Sponsor:
Shenyang Sunshine Pharmaceutical Co., LTD.
Collaborator:
The Fifth Affiliated Hospital of Guangzhou Medical University